Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CorMedix (CRMD) EBIT Margin (2016 - 2025)

CorMedix's EBIT Margin history spans 14 years, with the latest figure at 45.97% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 452.0% year-over-year to 45.97%; the TTM value through Dec 2025 reached 48.17%, up 10059.0%, while the annual FY2025 figure was 48.17%, 9959.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 45.97% at CorMedix, down from 49.24% in the prior quarter.
  • Across five years, EBIT Margin topped out at 233386.61% in Q2 2024 and bottomed at 102126.07% in Q3 2022.
  • The 5-year median for EBIT Margin is 28.7% (2024), against an average of 8910.22%.
  • The largest annual shift saw EBIT Margin surged 21763242bps in 2023 before it plummeted -23333743bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 13795.16% in 2021, then crashed by -105bps to 28244.66% in 2022, then skyrocketed by 544bps to 125537.59% in 2023, then plummeted by -100bps to 41.45% in 2024, then rose by 11bps to 45.97% in 2025.
  • Per Business Quant, the three most recent readings for CRMD's EBIT Margin are 45.97% (Q4 2025), 49.24% (Q3 2025), and 49.18% (Q2 2025).